소화제 및 정장제 시장 : 기회, 성장 촉진요인, 산업 동향 분석 예측(2024-2032년)

The Global Digestive And Intestinal Remedies Market was valued at USD 19.5 billion in 2023 and is projected to grow at a CAGR of 3.5% from 2024 to 2032. The increasing prevalence of gastrointestinal diseases drives this market. For instance, the Canadian Digestive Health Foundation reports that nearly 17% of Canadian adults suffer from GERD. Symptoms include chest pain, chronic cough, heartburn, sleep apnea, regurgitation, and belching. High intake of processed foods and being overweight contribute to this condition, leading to a higher demand for digestive and intestinal remedies.

Conditions such as GERD, irritable bowel syndrome (IBS), peptic ulcers, constipation, diarrhea, inflammatory bowel disease (IBD), and gastroenteritis often require remedies like digestive enzymes, anti-diarrheal medications, and fiber supplements. These remedies are essential for managing these ailments. The over-the-counter availability of these remedies boosts their adoption rate. The digestive medicines segment dominated the market, generating USD 10.3 billion in revenue in 2023. Digestive medicines, including both pharmaceutical and over-the-counter drugs, are formulated to alleviate a range of digestive issues.

These formulations effectively relieve symptoms such as heartburn, indigestion, bloating, constipation, and diarrhea. Many digestive medicines, like antacids and proton pump inhibitors (PPIs), are available over the counter, allowing individuals to access them for immediate relief without a prescription. Extensive research and a long history of use have cemented the reputation of these medicines for safety in both short-term and long-term applications. The market share of digestive and intestinal remedies is segmented into offline and online distribution channels.

The online segment is anticipated to reach USD 6 billion by 2032. Online platforms enable consumers to purchase digestive and intestinal remedies from home, eliminating the need for a pharmacy visit. These platforms operate 24/7, ensuring remedies are accessible anytime, which is beneficial for those experiencing symptoms outside regular hours.

The internet has become a primary source of health information, leading consumers to research digestive health issues and remedies online. This increased awareness influences their purchasing decisions on digital platforms.The rise in telemedicine and online consultations allows healthcare providers to prescribe digestive remedies, which patients can promptly purchase online, further fueling market growth.

In 2023, the U.S. accounted for a significant USD 7.4 billion share of the digestive and intestinal remedies market. Leading companies in the U.S. focus on developing advanced formulations, particularly in areas like proton pump inhibitors (PPIs) and probiotics, emphasizing longer-lasting effects, reduced side effects, and enhanced efficacy. This focus is expected to bolster the U.S. market.Social media, health blogs, and online forums play a crucial role in educating consumers about digestive health, fostering informed purchasing decisions. The U.S. is poised to maintain its dominance in the market, driving both growth and innovation.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rise in incidence of gastrointestinal disorders
    • 3.2.1.2 Growing demand for related over-the-counter products
    • 3.2.1.3 Changes in natural food habits
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Availability of alternative therapies for gastrointestinal diseases
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Digestive medicines
• 5.3 Remedies against gastrointestinal complaints
• 5.4 Natural and synthetic agents

Chapter 6 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Adult
• 6.3 Pediatric

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Offline
• 7.3 Online

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Bayer AG
• 9.3 C.H. Boehringer Sohn AG & Co. KG.
• 9.4 China Resources Pharmaceutical Group Limited
• 9.5 Eli Lilly and Company
• 9.6 GlaxoSmithKline plc
• 9.7 Johnson & Johnson
• 9.8 Menarini Group
• 9.9 Merck & Co, Inc.
• 9.10 Pfizer Inc.
• 9.11 The Procter & Gamble Company
• 9.12 Reckitt Benckiser Group plc (RB)
• 9.13 Sanofi S.A.
• 9.14 Taisho Pharmaceutical Holdings Co., Ltd.
• 9.15 Takeda Pharmaceutical Company Limited